These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Phenomenon of synergism of immunodepressive drugs (addition of campath to the protocol of immunodepression)]. Goriaĭnov VA; Kaabak MM; Shishlo LA; Marchenko AL Ter Arkh; 2009; 81(8):78-80. PubMed ID: 19799207 [TBL] [Abstract][Full Text] [Related]
26. [Monoclonal antibodies in renal transplantation]. Bonvoisin C; Weekers L; Grosch S; Krzesinski JM Rev Med Liege; 2009; 64(5-6):287-92. PubMed ID: 19642461 [TBL] [Abstract][Full Text] [Related]
27. The CARI guidelines. Calcineurin inhibitors in renal transplantation: the addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients. Webster AC; Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S75-84. PubMed ID: 17316285 [No Abstract] [Full Text] [Related]
28. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Ciancio G; Gaynor JJ; Roth D; Kupin W; Hanson L; Tueros L; Zarak A; Ruiz P; Burke GW Transplant Proc; 2010 Nov; 42(9):3503-6. PubMed ID: 21094804 [TBL] [Abstract][Full Text] [Related]
29. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience. Ji SM; Li LS; Cheng Z; Cheng DR; Sun QQ; Chen JS; Sha GZ; Liu ZH Transplant Proc; 2007 Jun; 39(5):1396-401. PubMed ID: 17580147 [TBL] [Abstract][Full Text] [Related]
30. Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center. Campos A; Lage E; Hinojosa R; Ordóñez A; Cisneros JM; Cabezón S; Gómez S; Aguilera A; Arana E; Cayuela A Transplant Proc; 2005 Apr; 37(3):1548-9. PubMed ID: 15866669 [TBL] [Abstract][Full Text] [Related]
31. Effects of combined immune therapy on survival and Th1/Th2 cytokine balance in rat orthotopic liver transplantation. Cao H; Liu H; Wu ZY Chin Med J (Engl); 2007 Oct; 120(20):1809-12. PubMed ID: 18028776 [TBL] [Abstract][Full Text] [Related]
32. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788 [TBL] [Abstract][Full Text] [Related]
33. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. Waldmann TA J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565 [TBL] [Abstract][Full Text] [Related]
34. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects]. ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094 [TBL] [Abstract][Full Text] [Related]
35. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Sandrini S Clin Transplant; 2005 Dec; 19(6):705-10. PubMed ID: 16313313 [TBL] [Abstract][Full Text] [Related]
36. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Van Gelder T; Warlé M; Ter Meulen RG Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558 [TBL] [Abstract][Full Text] [Related]
37. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation. Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958 [TBL] [Abstract][Full Text] [Related]
39. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Wiseman LR; Faulds D Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389 [TBL] [Abstract][Full Text] [Related]